MedTrace Logo

Mifepristone and Misoprostol for 2nd Trimester Termination of Pregnancy in Burkina Faso

NCT03269279 · Status: UNKNOWN · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2019-05-30

No results posted yet for this study

Summary

The goal of this study is to examine the effectiveness and feasibility of a mifepristone-misoprostol medical abortion regimen in terminating pregnancies 13-22 weeks in Burkina Faso.

Conditions

  • Medical; Abortion, Fetus

Interventions

DRUG

Mifepristone

Medication used in conjunction with misoprostol for abortion

DRUG

Misoprostol

Medication used in conjunction with mifepristone for abortion

Sponsors & Collaborators

  • Gynuity Health Projects

    lead OTHER

Principal Investigators

  • Blandine Thieba, MD · SOGOB

  • Evelyne Komboigo, MD · SOGOB

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2017-05-20
Primary Completion
2019-12-31
Completion
2019-12-31

Countries

  • Burkina Faso

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03269279 on ClinicalTrials.gov